CL2013002794A1 - Compuestos derivados de espiro(indazol-5,4’-piperidin) sustituidos, inhibidores de acetil-coa carboxilasa y su composicion farmaceutica, util para tratar una enfermedad, afeccion o trastorno modulado por la inhibicion de acetil-coa carboxilasa tal como diabetes, enfermedad de higado graso no alcoholico (hgna) o resistencia hepatica a insulina. - Google Patents
Compuestos derivados de espiro(indazol-5,4’-piperidin) sustituidos, inhibidores de acetil-coa carboxilasa y su composicion farmaceutica, util para tratar una enfermedad, afeccion o trastorno modulado por la inhibicion de acetil-coa carboxilasa tal como diabetes, enfermedad de higado graso no alcoholico (hgna) o resistencia hepatica a insulina.Info
- Publication number
- CL2013002794A1 CL2013002794A1 CL2013002794A CL2013002794A CL2013002794A1 CL 2013002794 A1 CL2013002794 A1 CL 2013002794A1 CL 2013002794 A CL2013002794 A CL 2013002794A CL 2013002794 A CL2013002794 A CL 2013002794A CL 2013002794 A1 CL2013002794 A1 CL 2013002794A1
- Authority
- CL
- Chile
- Prior art keywords
- acetyl
- disease
- coa carboxylase
- pharmaceutical composition
- hgna
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 3
- 201000010099 disease Diseases 0.000 title 2
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 title 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 title 1
- 108010018763 Biotin carboxylase Proteins 0.000 title 1
- 206010022489 Insulin Resistance Diseases 0.000 title 1
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 230000002440 hepatic effect Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title 1
- JNPDDAGXRDGOQX-UHFFFAOYSA-N spiro[indazole-5,4'-piperidine] Chemical group N1CCC2(CC1)C=C1C=NN=C1C=C2 JNPDDAGXRDGOQX-UHFFFAOYSA-N 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Photographic Processing Devices Using Wet Methods (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a un Compuesto que presenta la estructura señalada más abajo, o una sal farmacéutica mente aceptable del mismo, y a una composición farmacéutica que lo comprende.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161478240P | 2011-04-22 | 2011-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013002794A1 true CL2013002794A1 (es) | 2013-12-27 |
Family
ID=46025823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013002794A CL2013002794A1 (es) | 2011-04-22 | 2013-09-27 | Compuestos derivados de espiro(indazol-5,4’-piperidin) sustituidos, inhibidores de acetil-coa carboxilasa y su composicion farmaceutica, util para tratar una enfermedad, afeccion o trastorno modulado por la inhibicion de acetil-coa carboxilasa tal como diabetes, enfermedad de higado graso no alcoholico (hgna) o resistencia hepatica a insulina. |
Country Status (42)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102695708B (zh) * | 2009-11-10 | 2014-10-15 | 辉瑞大药厂 | N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂 |
| CN102491974B (zh) * | 2011-12-12 | 2013-08-07 | 南京药石药物研发有限公司 | 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法 |
| AR095036A1 (es) | 2013-03-14 | 2015-09-16 | Kalyra Pharmaceuticals Inc | Compuestos analgésicos bicíclicos |
| BR112015028214A2 (pt) | 2013-05-10 | 2017-07-25 | Nimbus Apollo Inc | inibidores de acc e usos dos mesmos |
| JP6434498B2 (ja) | 2013-05-10 | 2018-12-05 | ギリアド アポロ， エルエルシー | Ａｃｃ阻害剤及びその使用 |
| CN105358152A (zh) * | 2013-05-10 | 2016-02-24 | 尼普斯阿波罗有限公司 | Acc抑制剂和其用途 |
| MX2016002479A (es) | 2013-09-12 | 2016-05-31 | Pfizer | Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris. |
| WO2015056782A1 (ja) | 2013-10-17 | 2015-04-23 | 塩野義製薬株式会社 | 新規アルキレン誘導体 |
| CN105814013A (zh) * | 2013-12-12 | 2016-07-27 | 卡利拉制药公司 | 双环烷基化合物及合成 |
| JP6741343B2 (ja) * | 2014-03-07 | 2020-08-19 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | プロペラン誘導体および合成 |
| CA2892342C (en) | 2014-05-22 | 2016-11-01 | Sylvain-Paul Morency | Tool and method for layer depalletizing |
| US10308609B2 (en) | 2014-09-17 | 2019-06-04 | Zeno Royalties & Milestones, LLC | Bicyclic compounds |
| RU2759916C2 (ru) * | 2015-12-31 | 2021-11-18 | Цзянсу Тасли Дии Фармасьютикал Ко., Лтд. | Применение триацетил-3-гидроксифениладенозина для получения фармацевтического лекарственного средства для предупреждения или лечения неалкогольной жировой болезни печени |
| CN106580986B (zh) * | 2016-11-28 | 2017-09-15 | 王保亮 | 一种治疗少弱精子症的药物组合物 |
| CN111094259B (zh) | 2017-05-15 | 2023-08-11 | 里科瑞尔姆Ip控股有限责任公司 | 止痛化合物 |
| RU2020116458A (ru) * | 2017-11-21 | 2021-12-23 | Пфайзер Инк. | Кристаллическая соль 2-амино-2-(гидроксиметил)пропан-1,3-диола и 4-(4-(1-изопропил-7-оксо-1,4,6,7-тетрагидроспиро[индазол-5,4ʼ-пиперидин]-1ʼ-карбонил)-6-метоксипиридин-2-ил)бензойной кислоты |
| CN111574530B (zh) * | 2020-04-21 | 2022-07-26 | 徐州医科大学 | 一种acc抑制剂及其医药用途 |
| WO2024140923A1 (zh) * | 2022-12-30 | 2024-07-04 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
| WO2024213044A1 (en) * | 2023-04-14 | 2024-10-17 | Beijing Double-Crane Runchuang Technology Co., Ltd. | Azacyclo-carbonyl-fused ring derivatives and use thereof |
| WO2025036472A1 (en) * | 2023-08-16 | 2025-02-20 | Pharmaengine, Inc. | Spirocyclic mta-cooperative prmts inhibitor |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0901786B1 (en) | 1997-08-11 | 2007-06-13 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
| HUP0303376A3 (en) | 2001-02-28 | 2007-08-28 | Merck & Co Inc | Acylated piperidine derivatives as melanocortin-4 receptor agonists, and pharmaceutical compositions containing them and use thereof |
| HRP20040716A2 (en) | 2002-02-27 | 2005-02-28 | Pfizer Products Inc. | Acc inhibitors |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| WO2004092179A1 (ja) | 2003-04-14 | 2004-10-28 | Nippon Soda Co. Ltd. | スピロ誘導体、製造法および抗酸化薬 |
| JP2005119987A (ja) | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| BRPI0510284A (pt) | 2004-05-12 | 2007-10-30 | Pfizer Prod Inc | derivados de prolina e seu uso como inibidores da dipeptidil peptidase iv |
| WO2005113069A2 (en) | 2004-05-14 | 2005-12-01 | Research Development Foundation | Use of circumin and analogues as inhibitors of acc2 |
| BRPI0510273A (pt) | 2004-05-25 | 2007-10-30 | Pfizer Prod Inc | derivados de tetraazabenzo[e]azuleno e análogos destes |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| EP1910375B1 (en) | 2005-07-19 | 2011-05-11 | Merck Sharp & Dohme Corp. | Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors |
| WO2007013691A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | スピロ環化合物 |
| EP1951251B1 (en) | 2005-11-18 | 2010-12-29 | Merck Sharp & Dohme Corp. | Spirohydantoin aryl cgrp receptor antagonists |
| CA2641766A1 (en) | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| SI2463283T1 (sl) | 2006-04-20 | 2014-09-30 | Pfizer Products Inc. | Kondezirane fenil amino heterociklične spojine za preprečevanje in zdravljenje bolezni, ki jih posreduje glukokinaza |
| US20090270435A1 (en) | 2006-11-29 | 2009-10-29 | Jeffrey Wayne Corbett | Spiroketone Acetyl-CoA Carboxylase Inhibitors |
| PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| US20100113418A1 (en) * | 2007-02-20 | 2010-05-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2008125945A2 (en) | 2007-04-12 | 2008-10-23 | Pfizer Inc. | 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| WO2009144555A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| CA2729412A1 (en) * | 2008-07-04 | 2010-01-07 | Banyu Pharmaceutical Co., Ltd. | Novel spirochromanone carboxylic acids |
| EP2310015A4 (en) | 2008-07-14 | 2011-10-26 | Cropsolution Inc | ACETYL-COENZYME-CARBOXYLASE MODULATORS AND METHODS OF USE THEREOF |
| WO2010013161A1 (en) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Fluorinated heteroaryls |
| CN102149717B (zh) | 2008-08-28 | 2014-05-14 | 辉瑞大药厂 | 二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物 |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| NZ595024A (en) | 2009-03-11 | 2013-01-25 | Pfizer | Benzofuranyl derivatives used as glucokinase inhibitors |
| WO2010103438A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| CA2754523A1 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| EP2427448A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
| EP2427450A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
| JP2012528847A (ja) | 2009-06-05 | 2012-11-15 | ファイザー・インク | Ｇｐｒ１１９調節因子としてのｌ−（ピペリジン−４−イル）−ピラゾール誘導体 |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| CN102695708B (zh) * | 2009-11-10 | 2014-10-15 | 辉瑞大药厂 | N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂 |
| WO2011058473A1 (en) * | 2009-11-10 | 2011-05-19 | Pfizer Inc. | N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| PL2621493T3 (pl) * | 2010-09-30 | 2017-01-31 | Pfizer Inc. | N1-pirazolospiroketonowe inhibitory karboksylazy acetylo-CoA |
-
2012
- 2012-04-09 KR KR1020137030875A patent/KR101567659B1/ko not_active Expired - Fee Related
- 2012-04-09 CU CU20130126A patent/CU24164B1/es active IP Right Grant
- 2012-04-09 MX MX2013012313A patent/MX348860B/es active IP Right Grant
- 2012-04-09 ES ES12718387.9T patent/ES2561452T3/es active Active
- 2012-04-09 SI SI201230417T patent/SI2699576T1/sl unknown
- 2012-04-09 GE GEAP201213267A patent/GEP20166474B/en unknown
- 2012-04-09 DK DK12718387.9T patent/DK2699576T3/en active
- 2012-04-09 JP JP2014505745A patent/JP5657174B2/ja active Active
- 2012-04-09 MA MA36357A patent/MA35061B1/fr unknown
- 2012-04-09 PL PL12718387T patent/PL2699576T3/pl unknown
- 2012-04-09 MY MYPI2013003372A patent/MY162167A/en unknown
- 2012-04-09 CA CA2831380A patent/CA2831380C/en active Active
- 2012-04-09 CN CN201610487378.8A patent/CN106117205B/zh not_active Expired - Fee Related
- 2012-04-09 AU AU2012245996A patent/AU2012245996B2/en not_active Ceased
- 2012-04-09 PE PE2013002387A patent/PE20141187A1/es not_active Application Discontinuation
- 2012-04-09 AP AP2013007129A patent/AP3499A/xx active
- 2012-04-09 HR HRP20151397TT patent/HRP20151397T1/hr unknown
- 2012-04-09 HU HUE12718387A patent/HUE028602T2/hu unknown
- 2012-04-09 PH PH1/2013/501941A patent/PH12013501941A1/en unknown
- 2012-04-09 EP EP12718387.9A patent/EP2699576B1/en active Active
- 2012-04-09 WO PCT/IB2012/051732 patent/WO2012143813A1/en active Application Filing
- 2012-04-09 PT PT127183879T patent/PT2699576E/pt unknown
- 2012-04-09 CN CN201280019621.3A patent/CN103492388A/zh active Pending
- 2012-04-09 ME MEP-2015-214A patent/ME02312B/me unknown
- 2012-04-09 RS RS20160026A patent/RS54526B1/en unknown
- 2012-04-09 EA EA201391288A patent/EA022375B1/ru not_active IP Right Cessation
- 2012-04-09 NZ NZ616156A patent/NZ616156A/en not_active IP Right Cessation
- 2012-04-09 SG SG2013075148A patent/SG194142A1/en unknown
- 2012-04-18 TW TW101113766A patent/TWI464171B/zh not_active IP Right Cessation
- 2012-04-19 UY UY0001034027A patent/UY34027A/es not_active Application Discontinuation
- 2012-04-20 AR ARP120101364A patent/AR086198A1/es unknown
- 2012-04-21 US US13/452,839 patent/US8802688B2/en active Active
- 2012-09-04 UA UAA201311822A patent/UA107753C2/ru unknown
-
2013
- 2013-09-12 CR CR20130464A patent/CR20130464A/es unknown
- 2013-09-27 CL CL2013002794A patent/CL2013002794A1/es unknown
- 2013-09-27 TN TNP2013000393A patent/TN2013000393A1/fr unknown
- 2013-10-17 IL IL228949A patent/IL228949A/en active IP Right Grant
- 2013-10-18 GT GT201300258A patent/GT201300258A/es unknown
- 2013-10-18 NI NI201300111A patent/NI201300111A/es unknown
- 2013-10-21 DO DO2013000243A patent/DOP2013000243A/es unknown
- 2013-10-24 CO CO13252716A patent/CO6801757A2/es active IP Right Grant
- 2013-11-22 EC ECSP13013038 patent/ECSP13013038A/es unknown
-
2014
- 2014-07-08 US US14/325,420 patent/US20140323730A1/en not_active Abandoned
-
2015
- 2015-01-09 US US14/593,370 patent/US20150112068A1/en not_active Abandoned
- 2015-08-07 US US14/820,884 patent/US20150336958A1/en not_active Abandoned
-
2016
- 2016-01-14 CY CY20161100038T patent/CY1117122T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013002794A1 (es) | Compuestos derivados de espiro(indazol-5,4’-piperidin) sustituidos, inhibidores de acetil-coa carboxilasa y su composicion farmaceutica, util para tratar una enfermedad, afeccion o trastorno modulado por la inhibicion de acetil-coa carboxilasa tal como diabetes, enfermedad de higado graso no alcoholico (hgna) o resistencia hepatica a insulina. | |
| CR20140036A (es) | Compuesto inhibidor de la señalización de la trayectoria notch | |
| CL2013003513A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de amida de formula definida o una sal del mismo y un lubricante de sal no metalica; metodo para su preparacion, util para inhibir el crecimiento de celulas con cancer. | |
| AR089482A1 (es) | Composicion antimicrobiana y metodo para prolongar la vida util del agua, alimentos/piensos o ingredientes de alimentos/piensos | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
| BR112015000106A2 (pt) | moduladores heterocíclicos de síntes de lipídio | |
| IN2014CN03506A (es) | ||
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| ECSP12012097A (es) | Derivados de fumarato de ácido graso y sus usos | |
| CL2012002319A1 (es) | Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras. | |
| EP4397659A3 (en) | Preparation containing tetracyclic compound at high dose | |
| ECSP15028917A (es) | Compuesto heterocíclico | |
| MX2015008565A (es) | Derivados de 3-alquil-5-fluoro-4-sustituido-imino-3,4-dihidropirim idin-2(1h)-ona como fungicidas. | |
| AR087451A1 (es) | Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes | |
| EA201270216A1 (ru) | Фармацевтический состав | |
| BR112014003587A2 (pt) | derivados de 5-flúor-4-imino-3-(substituído)-3,4-di-hidropirimidin-2(1h)ona | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| CO6420351A2 (es) | Composiciones plaguicidas | |
| BR112015015515A2 (pt) | composições fungicidas sinérgicas | |
| AR092971A1 (es) | Inhibidores de agrecanasa | |
| BR112013018938A2 (pt) | agente antifúngico tópico | |
| AR085093A1 (es) | Composicion pesticida y metodo para controlar plagas | |
| UA103290C2 (ru) | Фармацевтическая композиция ибупрофена для инъекции |